SIETES :: 93213 citas

Resultados de la búsqueda por White,CM

1.

Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, Lazarus SC, Blake KV, Lang JE. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma. A systematic review and meta-analysis. JAMA 2018;319:10 de abril. [Ref.ID 102670]

2.

Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015;238:329-35. [Ref.ID 98738]

3.

Sobieraj DM, Lee S, Coleman CI, Tongbram V, Chen W, Colby J, Kluger J, Makanji S, Ashaye AO, White CM. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review. Ann Intern Med 2012;156:720-7. [Ref.ID 92954]

4.

Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, Phung OJ, White CM. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II - Receptor blockers for ischemic heart disease. Ann Intern Med 2009;151:861-71. [Ref.ID 87424]

5.

Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 2007;41:599-605. [Ref.ID 80019]

6.

Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk. A meta-analysis. JAMA 2006;295:74-80. [Ref.ID 76501]

7.

McBride BF, White CM. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET. J Clin Pharmacol 2004;45:6-24. [Ref.ID 72312]

8.

McBride BF, White CM. levosimendan: implications for clinicians. J Clin Pharmacol 2003;43:1071-81. [Ref.ID 67619]

9.

White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-70. [Ref.ID 63368]

10.

Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002;41:207-24. [Ref.ID 61487]

11.

Caron MF, Kluger J, White CM. Amiodarone in the new AHA guidelines for ventricular tachyarrhythmias. Ann Pharmacother 2001;35:1248-54. [Ref.ID 59280]

12.

Giri S, White CM, Dunn AB, Felton K, Freeman-Bosco L, Reddy P, Tsikouris JP, Wilcox HA, Kluger J. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet 2001;357:830-6. [Ref.ID 55603]

13.

Song JC, White CM. Do HMG-CoA reductase inhibitors affect fibrinogen?. Ann Pharmacother 2001;35:236-41. [Ref.ID 55048]

14.

Dunn AB, White CM, Reddy P, Chow MSS, Kluger J. Efficacy and cost analysis of ibutilide. Ann Pharmacother 2000;34:1233-7. [Ref.ID 53841]

15.

White CM. Prevention of suboptimal ß-blocker treatment in patients with myocardial infarction. Ann Pharmacother 1999;33:1063-72. [Ref.ID 47730]

16.

White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 1999;39:111-8. [Ref.ID 43524]